Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions